Q3 FY2026 · ended Sep 30, 2026 · Revenue $62.28M, -45.2% YoY · Filed Oct 28, 2026
Mimedx Group, Inc. (MDXG) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $62.3 million and a net loss of $8.7 million. As of Sep 30, 2026 it held $120.8 million in cash and investments and $0 in total debt.
Revenue
$62.28M
-45.2% vs year-ago quarter
Net income
$-8.68M
-151.8% vs year-ago quarter
Operating cash flow
$3.92M
-86.6% vs year-ago quarter
Free cash flow
—
EPS
$-0.06
-154.5% vs year-ago quarter
Dividend per share
None
Shares outstanding
145.93M
-1.5% vs year-ago quarter
Net cash
$120.79M
Q3 FY2026
Operating margin
-8.3%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- MDXG (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Marietta, GA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1376339
- Former names
- Alynx, Co. (until Apr 2, 2008)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $62.3M | $64.4M | $59.0M | $118.1M | $113.7M |
| Operating income | -$11.7M | -$18.5M | -$16.0M | $21.1M | $22.2M |
| Net income | -$8.7M | -$14.8M | -$10.9M | $15.2M | $16.7M |
| Diluted EPS | -$0.06 | -$0.10 | -$0.07 | $0.10 | $0.11 |
| Operating cash flow | $3.9M | -$10.0M | $1.9M | $25.0M | $29.3M |
| Total assets | $264.6M | $281.0M | $308.7M | $342.7M | $319.0M |
| Total liabilities | $53.5M | $65.0M | $65.7M | $86.1M | $80.0M |
| Stockholders' equity | $211.1M | $216.0M | $242.9M | $256.5M | $238.9M |
| Cash and investments | $120.8M | $135.8M | $159.8M | $166.1M | $142.1M |
| Total debt | $0 | $17.2M | $17.6M | $22.6M | $18.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Oct 28, 2026 | Oct 28, 2026 |
| 10-Q | Quarterly report | Oct 28, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 16, 2026 | Oct 15, 2026 |
| 8-K/A |
Amended current report
Material agreement, Regulation FD disclosure
|
Aug 11, 2026 | Jul 29, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Jul 29, 2026 | Jul 29, 2026 |
| 10-Q | Quarterly report | Jul 29, 2026 | Jun 30, 2026 |
All 1000 Mimedx Group, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.